A Longer Life With Liver Cancer
Could anti-IL-6 antibodies that downregulate PD-L1 expression prolong immunotherapy?
Luke Turner | | Quick Read
Statistics for patients diagnosed with liver cancer are bleak – only 18.4 percent survive past five years in the US (1). The most common form of primary liver cancer, hepatocellular carcinoma (HCC), is notoriously difficult to treat, with multikinase inhibitors, such as sorafenib and regorafenib, extending overall survival by less than three months. But the future looks brighter; new research from a team led by Mien-Chie Hung at the University of Texas MD Anderson Cancer Center shows that a cellular pathway closely linked to cancer may prolong immunotherapy and reduce its side effects.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.